CoChat

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma

Open access
Simbulan-Rosenthal, Cynthia M., Dakshanamurthy, Sivanesan, Gaur, Anirudh, Chen, You-Shin, Fang, Hong-Bin, Abdussamad, Maryam, Zhou, Hengbo, Zapas, John, Calvert, Valerie, Petricoin, Emanuel F., Atkins, Michael B., Byers, Stephen W., Rosenthal, Dean S. · 2017 · Oncotarget
Cited by 63

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Cynthia M. Simbulan-Rosenthal 1,* , Sivanesan Dakshanamurthy 1,2,* , Anirudh Gaur 1 , You-Shin Chen 1 , Hong-Bin Fang 3 , Maryam Abdussamad 4 , Hengbo Zhou 4 , John Zapas 4 , Valerie Calvert 5 , Emanuel F. Petricoin 5 , Michael B. Atkins 2 , Stephen W. Byers 1,2 and Dean S. Rosenthal 1 1 Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, USA 2 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA 3 Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA 4 MedStar Franklin Square Medical Center, Baltimore, MD, USA 5 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA * These authors are co-first authors Correspondence to: Dean S. Rosenthal, email: // Keywords : mebendazole, drug repurposing, melanoma, ERK pathway, BRAF Received : March 31, 2016 Accepted : October 13, 2016 Published : February 02, 2017 Abstract Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAF WT and BRAF V600E . We find that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAF WT -NRAS Q61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation. Reverse Phase Protein Array (RPPA) and immunoblot analyses show that both trametinib and MBZ inhibit the MAPK pathway, and cluster analysis revealed a protein cluster showing strong MBZ+trametinib - inhibited phosphorylation of MEK and ERK within 10 minutes, and its direct and indirect downstream targets related to stress response and translation, including ElK1 and RSKs within 30 minutes. Downstream ERK targets for cell cycle, including cMYC, were down-regulated, consistent with S- phase suppression by MBZ+trametinib, while apoptosis markers, including cleaved caspase-3, cleaved PARP and a sub-G1 population, were all increased with time. These data suggest that MBZ, a well-tolerated off-patent approved drug, should be considered as a therapeutic option in combination with trametinib, for patients with NRAS Q61mut or other non-V600E BRAF mutant melanomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.14990

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 63

Metadata

Authors
Simbulan-Rosenthal, C. M., Dakshanamurthy, S., Gaur, A., Chen, Y.-S., Fang, H.-B., Abdussamad, M., Zhou, H., Zapas, J., Calvert, V., Petricoin, E. F., Atkins, M. B., Byers, S. W., & Rosenthal, D. S.
Venue
Oncotarget
Published
2017-02-02
Volume
8
Issue
8
Pages
12576-12595
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2584349229
Cited by
63
References
7
FWCI
1.94
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.